新型降脂药人前蛋白转化酶枯草溶菌素9抑制剂与动脉粥样硬化性心血管疾病、静脉血栓栓塞疾病关系的研究进展

随着生活方式的改变，心脑血管疾病逐渐成为全人类死亡的“头号杀手”，高于恶性肿瘤、糖尿病等。血脂的升高尤其是低密度脂蛋白胆固醇(LDL-C)的升高与动脉粥样硬化性心血管疾病(ASCVD)的发生、发展息息相关。现有的专家共识、指南提出他汀类药物是降低LDL-C的一线用药，但仍可能会发生复发性缺血事件。人前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂作为一类新型降脂药，有显著降低血LDL-C水平，同时又可降低脂蛋白(a)的水平，又与ASCVD与静脉血栓栓塞疾病(VTE)的发病可能相关。本文将系统地阐述新型降脂药PCSK9抑制剂与ASCVD、VTE的关系研究进展。

Research progress on the relationship between the new lipid-lowering drug PCSK9 inhibitor and ASCVD and VTE

With changes in lifestyle, cardiovascular and cerebrovascular diseases have gradually become the "no. 1 killer" of all hu.man deaths, higher than malignant tumors and diabetes. The increase in blood lipids, especially the increase in low-density lipoprotein cholesterol (LDL-C) is closely related to the occurrence and development of atherosclerotic cardiovascular disease (ASCVD). Existing ex.pert consensus and guidelines suggest that statins are the first-line drugs for lowering LDL-C, but recurrent ischemic events may still oc. cur. Human proprotein convertase subtilisin 9 (PCSK9) inhibitors, as a new class of lipid-lowering drugs, can significantly reduce blood LDL-C levels and reduce lipoprotein (a) levels and are related to ASCVD and venous thromboembolic disease (VTE). This article system.atically describes the research progress on the relationship between new lipid-lowering drug PCSK9 inhibitors and SCVD and VTE.